Literature DB >> 10622554

Hepatitis C: the clinical spectrum of the disease.

P Marcellin1.   

Abstract

The hepatitis C virus (HCV) infects nearly 170 million people worldwide and is responsible for approximately 20% of cases of acute hepatitis and 70% of cases of chronic hepatitis. Acute hepatitis is icteric in only 20% of patients and is rarely severe. Eighty-five percent of infected patients develop chronic infection which is generally asymptomatic, resulting in most cases in fortuitous diagnosis, which may be made at a late stage. Twenty-five percent of the HCV chronic carriers have persistently normal serum alanine aminotransferase (ALT) levels despite having detectable HCV RNA in serum; 75% have elevated ALT levels. The former patients usually have mild histologic lesions, probably with a good long-term prognosis. In the latter patients, a liver biopsy is the most accurate way to distinguish patients with mild chronic hepatitis from those with moderate or severe chronic hepatitis. While most patients with mild chronic hepatitis have a slowly progressive liver disease, the patients with moderate or severe chronic hepatitis may develop cirrhosis within a few years. In patients with HCV-related cirrhosis, the incidence of hepatocellular carcinoma is 2-5% per year. At presently, HCV-related end-stage cirrhosis is the first cause of liver transplantation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10622554     DOI: 10.1016/s0168-8278(99)80368-7

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  61 in total

1.  Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients.

Authors:  Mitsuhiro Takimoto; Shogo Ohkoshi; Takafumi Ichida; Yasuo Takeda; Minoru Nomoto; Hitoshi Asakura; Akira Naito; Shigeki Mori; Kojiro Hata; Kentaro Igarashi; Hidenori Hara; Hironobu Ohta; Kenji Soga; Toshiaki Watanabe; Tomoteru Kamimura
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

Review 2.  Treatment of hepatitis C. The 2002 French consensus.

Authors:  D Dhumeaux; P Marcellin; E Lerebours
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

Review 3.  Host genetic basis for hepatitis C virus clearance: a role for blood collection centers.

Authors:  Suganya Selvarajah; Leslie H Tobler; Graham Simmons; Michael P Busch
Journal:  Curr Opin Hematol       Date:  2010-11       Impact factor: 3.284

Review 4.  Treatment of acute HCV infection.

Authors:  Jason Grebely; Gail V Matthews; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-22       Impact factor: 46.802

Review 5.  Peginterferon alpha-2a (40KD) plus ribavirin: a review of its use in the management of patients with chronic hepatitis C and persistently 'normal' ALT levels.

Authors:  Gillian M Keating; Greg L Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Liver enzyme alteration: a guide for clinicians.

Authors:  Edoardo G Giannini; Roberto Testa; Vincenzo Savarino
Journal:  CMAJ       Date:  2005-02-01       Impact factor: 8.262

7.  Elderly recipients of hepatitis C positive renal allografts can quickly develop liver disease.

Authors:  Tanya R Flohr; Hugo Bonatti; Tjasa Hranjec; Doug S Keith; Peter I Lobo; Sean C Kumer; Timothy M Schmitt; Robert G Sawyer; Timothy L Pruett; John P Roberts; Kenneth L Brayman
Journal:  J Surg Res       Date:  2011-11-19       Impact factor: 2.192

8.  Nested restriction site-specific PCR to detect and type hepatitis C virus (HCV): a rapid method to distinguish HCV subtype 1b from other genotypes.

Authors:  L Krekulova; V Rehak; A E Wakil; E Harris; L W Riley
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

9.  Distinguishing acute from chronic and resolved hepatitis C virus (HCV) infections by measurement of anti-HCV immunoglobulin G avidity index.

Authors:  S Klimashevskaya; A Obriadina; T Ulanova; G Bochkova; A Burkov; A Araujo; Susan L Stramer; Leslie H Tobler; Michael P Busch; Howard A Fields
Journal:  J Clin Microbiol       Date:  2007-08-22       Impact factor: 5.948

Review 10.  Enhancing our understanding of current therapies for hepatitis C virus (HCV).

Authors:  Neliswa A Gogela; Ming V Lin; Jessica L Wisocky; Raymond T Chung
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.